GlobalData estimates that the global cancer pain therapeutics market was valued at $2.4 billion in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4% over the next seven years, to reach $3.2 billion by 2017. This steady growth is primarily attributed to the strong pipeline with new firstin- class therapies. The current competitive landscape consists of branded products, generics and off-label drugs. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. The pipeline products are expected to provide better benefits, with innovative mechanisms of action. However, the generic availability and physician familiarity with opioids such as immediate-release morphine, NSAIDs and fentanyl will continue to dominate the cancer pain market. Essentially, the global cancer pain market is heading towards a phase of continuous growth, leveraging the current opportunities.
GlobalDatas analysis shows that the cancer pain therapeutics pipeline is strong, with 23 molecules in various phases of clinical development including 11 first-in-class molecules. Amongst these 11 first-inclass molecules, three molecules are in late stage and the remaining are in the early stages of clinical development. The late stage pipeline molecule Tapentadol (Nucynta ER), an opioid agonist, has been filed for regulatory approval and is expected to launch by 2012. Ereska, Sativex and tetrodotoxin (TTX) are first-in-class products in Phase III, and are expected to be launched by 2015. These products will be responsible for the growth of the cancer pain therapeutics market post-2015. Although the market is adequately served by the current treatment options, the cancer pain therapeutics pipeline will uncover opportunities for the new entrants.
For Sample Pages, please click or add the below link to your browser:
The cancer pain therapeutics market has moderate unmet need, as the present market is well served with current treatment options. However, there is scope for new products in the market. The marketed products have prolonged duration of therapy, risk of addiction, and fear among patients that pain treatment can interfere with their cancer treatment. These are the factors which pose a significant barrier to the patients. Thus, there is a need for novel products which can fill these voids created by the currently marketed products. The generics will continue to dominate the market due to their easy availability, physician familiarity and physicians adherence to WHO pain ladder guidelines.
GlobalData, the industry analysis specialist, has released its new report, Cancer Pain Therapeutics Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global cancer pain therapeutics market. The report identifies the key trends shaping and driving the global cancer pain therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer pain therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782